Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 23.02.2026 FTFX IE00BD5HBQ97 63,402.00 USD 1,681,364.53 26.519  ...

DALLAS--(BUSINESS WIRE)--Friday just got a whole lot sweeter! Dickey’s Barbecue Pit is bringing fans a deal as sweet as the fruit itself on Friday, Feb. 27 by offering a FREE scoop of Miss Ollie’s Secret Strawberry Ice Cream cup with the purchase of any Classic Sandwich or new Smoked Ham & Cheddar sandwich in celebration of National Strawberry Day. Available at participating Dickey’s restaurants across the U.S., this berry barbecue bargain is redeemable for Big Yellow Cup rewards members us...

TORONTO--(BUSINESS WIRE)--As We Do Chocolate Company Inc. officially announced its launch today, aiming to fill a massive gap in the North American market by becoming Canada’s premier scaled, chef-led, bean-to-bar chocolate producer. Founded by world-class chef Brandon Olsen and veteran entrepreneur Michael Held, the company is debuting with a Kickstarter pre-sale campaign launching on February 24th. While Canada is projected to consume over $5.4 billion in chocolate in 2025, nearly all premium...

NEW YORK--(BUSINESS WIRE)--ProCap Financial, Inc. (Nasdaq: BRR), the first publicly traded agentic finance firm, today announced it repurchased 155,561 shares of its common stock in the open market yesterday. The repurchases were done at an approximate 32% discount to Net Asset Value ("NAV"). The Company is committed to aggressively buying back stock for as long as BRR shares trade at a significant discount to NAV. "We are not going to sit on our hands while the market offers us the chance to b...

MIAMI--(BUSINESS WIRE)--Haley Garcia brings Garcia Real Estate Group, a 6-agent luxury team serving The Woodlands, Texas, to The Real Brokerage....

RALEIGH, N.C.--(BUSINESS WIRE)--Slate Medicines, Inc., a privately-held biotech company advancing next-generation therapeutics for headache disorders, today announced the close of a $130 million Series A financing, alongside the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody licensed from DartsBio Pharmaceuticals (Guangdong), Ltd. Slate Medicines is led by Chief Executive Officer and Board Director Gregory Oakes, a biopharma executive with more than 30 years of experience leading...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 Type: Fireside Chat Presentation Date/Time: March 2, 2026, 11:50 a.m. EST Leerink 2026 Global Healthcare Conference – March 8-11, 2026 Type: Fireside Chat Presentation Date/Time: March 9, 2026, 2:20 p.m. EST 2026 Jefferies Biotech on the Beach Summit – March 9-11, 2026...

NEW YORK, NY--(BUSINESS WIRE)--USA TODAY Co., Inc. ("USA TODAY Co.", "we", "us", "our", or the "Company") (NYSE: TDAY) today announced that its Chairman and Chief Executive Officer, Michael Reed, and its Chief Financial Officer, Trisha Gosser, will present at the following conference: The Citizens JMP Technology Conference Tuesday, March 3, 2026 1:00 p.m. ET / 10:00 a.m. PT San Francisco, California The video webcast of the conference will be accessible through the Investor Relations section of...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating CBI-1214, the company’s lead investigational therapy targeting LY6G6D in adults with microsatellite stable or microsatellite instability-low (MSS/MSI-L) colorectal cancer (CRC). LY6G6D is selectively expressed in CRC,...